Project Grant R44AI195215

The National Institute of Allergy and Infectious Diseases awarded Vivid Bioinnovations, PBC $307,074 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop HIVE-SEQ, a novel omics platform for profiling single HIV-infected cells.

HIVE-SEQ integrates the intact proviral DNA assay with single-cell and single-nucleus multi-omic profiling to identify and characterize cells carrying viable HIV proviruses across diverse tissues without requiring viral reactivation. The platform captures full-length proviral sequences alongside host cell transcriptomes and proteomes, preserving the natural, unstimulated state of infected cells. In Phase I, the recipient will transfer single-cell protocols to its R&D facility, validate workflows with reference standards, and establish standard operating procedures for processing blood and solid tissues including lymph nodes, brain, gut, and other clinically relevant sources. The work prioritizes access to the Last Gift cohort, a biorepository of tissues from people living with HIV who use opioids, to address an understudied population. In Phase II, the recipient will operate an in-house service laboratory to process real-world samples, enhance platform throughput and automation, refine data analysis pipelines for complex tissues and high sample volumes, and integrate improvements into a commercial-ready instrument and reagent kit.

Performance occurs in San Francisco, California, with a completion date of February 28, 2027. This is a Small Business Innovation Research Phase I award.